OIS INDEX: Trump Bump

OIS Index: Trump Bump - Eye On Innovation Article - OIS - Healthegy

The OIS Index closed at 962.42 on Tuesday, a week after Donald Trump’s election. Here’s how the collection of 29 publicly traded ophthalmology companies fared against larger indexes.

OIS Index = 12.7% increase
Russell 3000 = 2.6% increase
NASDAQ Biotech Index = 11.2 % increase
US Medical Device Index = 1% drop

OIS Index | Trump Bump

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

5 Factors for Evaluating Investments in the Retina Space

5 Factors for Evaluating Investments in the Retina Space

As Retina Innovators Look Outside US for Funding, Here’s What to Watch Out For

As Retina Innovators Look Outside US for Funding, Here’s What to Watch Out For

Why Link Between Cognition and Vision May Emerge as a Focus of Innovation

Why Link Between Cognition and Vision May Emerge as a Focus of Innovation

How Omega Ophthalmics Hopes to Redefine Use of the Capsular Bag with the Gemini Refractive Capsule

How Omega Ophthalmics Hopes to Redefine Use of the Capsular Bag with the Gemini Refractive Capsule

Glaukos' Bid for Avedro: What's Next

A Closer Look at Glaukos’ Bid for Avedro

OIS@ASRS Reporter's Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

OIS@ASRS Reporter’s Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

About The Author

Michael Lachman

Michael Lachman is President of EyeQ Research, which provides market research, analytics, and strategic advisory to ophthalmic companies and investors. Previously, he was a healthcare investment research analyst with Hambrecht & Quist, ThinkEquity Partners, and SAC Capital, and worked in business development, marketing, and R&D for Johnson & Johnson and Baxter.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.